ChemBriefBayer to buy Perfuse Therapeutics in up to $2.45 billion deal
Bayer announced plans to acquire biopharmaceutical firm Perfuse Therapeutics for up to $2.45 billion to bolster its ophthalmology pipeline. The deal includes a $300 million upfront payment plus additi
reuters · 2026-05-05 23:45